NCT07025850 2025-08-01
Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer
Fudan University
Phase 1/2 Not yet recruiting
Clinical Trials
19 trialsNCT05978102 2025-07-23
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1/2 Recruiting
NCT04963088 2025-06-26
TALENT
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Completed
NCT07010120 2025-06-13
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
West China Hospital
Phase 1/2 Recruiting
NCT06871527 2025-03-12
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06586099 2024-09-19
Tislelizumab with Azacitidine in the Treatment of R/R AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Withdrawn
NCT06456138 2024-06-13
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Shanghai Chest Hospital
Phase 1/2 Not yet recruiting
NCT06394791 2024-05-01
Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Not yet recruiting
NCT05842317 2024-02-09
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT06022692 2023-09-05
HEAIS001
Zhejiang Hospital
Phase 1/2 Completed
NCT05982834 2023-08-09
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
Fudan University
Phase 1/2 Unknown
NCT05699811 2023-04-28
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT05833984 2023-04-27
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Unknown
NCT04652440 2023-04-19
Ablation Combined With PD-1 in HCC: Phase II Study
Sun Yat-sen University
Phase 1/2 Unknown
NCT05746728 2023-04-06
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
Tongji Hospital
Phase 1/2 Unknown
NCT04782804 2022-08-18
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
Fudan University
Phase 1/2 Unknown
NCT05394415 2022-05-27
LATE
Jiangsu Cancer Institute & Hospital
Phase 1/2 Unknown
NCT04979663 2021-08-09
GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer
Fudan University
Phase 1/2 Unknown
NCT04922047 2021-06-11
TACBIN-01
RenJi Hospital
Phase 1/2 Unknown